Wave Life Scienc Stock Price, News & Analysis

Wave Life Sciences (Nasdaq: WVE) commenced an underwritten public offering to raise $250 million of ordinary shares and, for certain investors electing that option, pre-funded warrants to purchase ordinary shares on Dec. 8, 2025.

The company granted the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares and shares underlying pre-funded warrants. Jefferies, Leerink Partners and BofA Securities are joint book-running managers. The offering is subject to market and other conditions and will be made only by prospectus and prospectus supplement filed with the SEC.

Wave Life Sciences (Nasdaq: WVE) reported positive interim Phase 1 INLIGHT data for WVE-007 (INHBE) after a single 240 mg subcutaneous dose in individuals with mean baseline BMI ~32 kg/m2.

At Day 85, WVE-007 produced a 9.4% visceral fat reduction (p=0.02), 4.5% total body fat reduction (3.5 lbs; p=0.07), and a 3.2% lean mass increase (4.0 lbs; p=0.01). Mean Activin E fell >75% and maxed at 78% reduction, supporting once- or twice-yearly dosing. Safety was generally favorable up to 600 mg with no serious TEAEs. Phase 2 planning is underway; further 2026 follow-ups expected.

Wave Life Sciences (Nasdaq: WVE) will announce interim data from the ongoing Phase 1 INLIGHT trial of WVE-007 (INHBE) for obesity on Monday, December 8, 2025. A press release will be issued at 7:30 a.m. ET, followed by an investor conference call and webcast at 8:30 a.m. ET. Investors can access the live webcast via the company’s Investor Events page and an archived version will be available after the event.

This announcement covers timing and access for interim clinical data disclosure for WVE-007; no trial results or financial metrics are included in this notice.

Wave Life Sciences (Nasdaq: WVE) reported Q3 2025 results and pipeline updates on Nov 10, 2025. Key clinical readouts: WVE-007 (INHBE GalNAc-siRNA) produced dose-dependent Activin E reductions up to 85% at Day 29 with lowest-dose durability through six months, supporting once- or twice-year dosing; WVE-006 (AIMer for AATD) achieved AAT protein > 20 µM during acute response, basal AAT ~13 µM, wild-type M-AAT ~64% of serum AAT, and Z-AAT reduced by 60%. Cash was $196.2M at Sept 30, 2025, and subsequent $72.1M ATM proceeds plus committed GSK milestones extend runway into 2Q 2027. Multiple clinical data updates and regulatory filings expected through 2026, including WVE-N531 NDA planning and WVE-008 CTA filing.

Wave Life Sciences (Nasdaq: WVE) announced that management will participate in two investor conferences in November 2025.

Guggenheim 2nd Annual Healthcare Innovation Conference — Paul Bolno, MD, MBA, President and CEO, will speak in an analyst-led fireside chat on Tuesday, November 11, 2025 at 10:00 a.m. ET.

Jefferies London Healthcare Conference — Dr. Bolno will join an analyst-led fireside chat on Thursday, November 20, 2025 at 8:30 a.m. GMT / 3:30 a.m. ET and participate in an Anti-Obesity Panel at 9:00 a.m. GMT / 4:00 a.m. ET. Live webcasts and limited-time replays are available via the company’s Investors "Investor Events" page.

Wave Life Sciences (NASDAQ: WVE) will present preclinical data for WVE-007 (INHBE GalNAc-siRNA) at ObesityWeek® on November 6, 2025, showing a potential approach to drive fat loss while preserving muscle with once- or twice-yearly dosing.

Key preclinical findings: single-dose weight loss in DIO mice, visceral adipose reductions, adipocyte shrinkage, fewer pro-inflammatory macrophages (up to 80%), reduced fibrosis (58%), and doubled weight loss when combined with semaglutide. Early clinical INLIGHT results show dose-dependent Activin E decreases of 56–85% at Day 29 and durable reductions through six months; WVE-007 was reported as safe and well tolerated to date.

Wave Life Sciences (Nasdaq: WVE) will host a live webcast and conference call at 8:30 a.m. ET on Monday, November 10, 2025 to review third quarter 2025 financial results and provide business updates.

Investors and analysts can access the live event via the company’s Investor Events page and analysts may join the Q&A by phone using the audio-conferencing link. An archived webcast will be posted on the Wave Life Sciences website after the live presentation.

Wave Life Sciences (Nasdaq: WVE) corrected its Oct 29, 2025 release to report INLIGHT trial target engagement for WVE-007 (GalNAc-siRNA) in obesity.

Key clinical facts: single doses produced dose-dependent mean Activin E reductions of 85% (400 mg), 75% (240 mg), and 56% (75 mg) at day 29 (p<0.0001). Cohort 1 reductions were sustained through six months, supporting once- or twice-yearly dosing. WVE-007 is reported as safe and well tolerated to date. Multiple follow-up data milestones are expected between 4Q2025 and 2Q2026.

Additional updates: WVE-006 showed total AAT to 13 µM with 64% wild-type M-AAT after treatment and an individual >20 µM; WVE-008 (PNPLA3) CTA planned in 2026; company presented preclinical dual edit+silence modality.

Wave Life Sciences (Nasdaq: WVE) reported dose-dependent, highly significant Activin E reductions from its INLIGHT trial of WVE-007 for obesity: 85% (400 mg), 75% (240 mg) and 56% (75 mg) at day 29 post single dose, with Cohort 1 reductions sustained through six months. WVE-007 was described as generally safe and well tolerated to date and an independent committee supported expansion to a 600 mg cohort. Multiple INLIGHT body-composition and weight updates are planned starting 4Q 2025. Wave also announced WVE-008 (PNPLA3 RNA editing) with a CTA expected in 2026, and highlighted pipeline advances in RNA editing and combined edit/silence oligonucleotide constructs.